162 research outputs found
Factors associated with health status and exacerbations in COPD maintenance therapy with dry powder inhalers
Funding Information: J.K. reports grants, personal fees and non-financial support from AstraZeneca, GSK and Boehringer Ingelheim; grants and personal fees from Chiesi Pharmaceuticals and TEVA; grants from Mundipharma; personal fees from MSD and COVIS Pharma; and also holds 72.5% of shares in the General Practitioners Research Institute. H.W. has received grants from Boehringer Ingelheim, which is the financial and scientific partner of GPRI for the submitted study, and from AstraZeneca, Novartis and Chiesi for scientific projects in the area of COPD/asthma. S.B.-A. has received grants from TEVA, and personal fees from TEVA, Boehringer Ingelheim, AstraZeneca, GSK, Sanofi and Mylan. J.C.d.S. reports or personal fees from AstraZeneca, Bial, Boehringer Ingelheim, GSK, Medinfar, Mundipharma and Sanofi. B.C. received honorarium from GSK and Sanofi. J.v.C., L.D., I.v.G.-P., I.v.d.H., Y.J., M.K., B.M., K.S., N.S., M.H., B.M. and M.T.L. were employed by General Practitioners Research Institute (GPRI) at the time of the study. In the past three years (2019–2021), GPRI conducted investigator- and sponsor-initiated research funded by non-commercial organizations, academic institutes, and pharmaceutical companies (including AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Mundipharma, Novartis, and Teva). R.D. has received grants and personal fees from TEVA, Boehringer Ingelheim, AstraZeneca, GSK, Chiesi, Focus Care, and Glenmark. R.G. has received personal fees from AstraZeneca, GSK and Chiesi. E.D. holds 27.5% of shares in the General Practitioners Research Institute. M.G.P. receives grants from AstraZeneca, GSK and Boehringer Ingelheim. A.G. and A.d.l.H. are employees of Boehringer Ingelheim. F.L. received grants and personal fees from GSK, personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Menarini International, Novartis, Orion, and Trudell International, outside the submitted work. T.M. is an Assoicate Editor at npj Primary Care Respiratory Medicine. J.M. received grants from Boehringer Ingelheim, during the conduct of the study; and grants from AstraZeneca, Chiesi, Novartis, and GSK, outside the submitted work. D.P. reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Theravance and Zentiva (Sanofi Generics); grants from the British Lung Foundation, Respiratory Effectiveness Group, UK National Health Service, and AKL Research and Development Ltd; personal fees from Cipla, GlaxoSmithKline, Kyorin, Merck, Mundipharma, Airway Vista Secretariat, EPG Communication Holdings Ltd, FIECON Ltd, Fieldwork International, OM Pharma SA, PeerVoice, Phadia AB, Spirosure Inc, Strategic North Limited, Synapse Research Management Partners S.L., Talos Health Solutions, and WebMD Global LLC; non-financial support from Efficacy and Mechanism Evaluation programme and Health Technology Assessment; stock/stock options from AKL Research and Development Ltd, which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 92.61% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); and 5% shareholding in Timestamp, which develops adherence monitoring technology. M.R.-R. receives grants and personal fees from AstraZeneca and GSK; and personal fees from Boehringer Ingelheim, Chiesi, Menarini, Mundipharma, Novartis, Pfizer, TEVA and BIAL. I.T. reports grants and personal fees from GSK, AstraZeneca, Boehringer Ingelheim, Menarini, Novartis, Chiesi and Elpen. O.U. reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Edmond Pharma, Chiesi and GSK; grants from Edmond Pharma; and personal fees from Napp, Mundipharma, Sandoz, Takeda, Cipla, COVIS, Novartis, Mereobiopharma, Orion, and Menarini. S.B.-A. and T.M. are Associate Editors at npj Primary Care Respiratory Medicine, and I.T. is Editor in Chief. These authors were not involved in the journal’s review of, or decisions related to, this manuscript.Peer reviewedPublisher PD
Search for New Particles Decaying to Dijets at CDF
We have used 106 pb^-1 of data collected with the Collider Detector at
Fermilab to search for new particles decaying to dijets. We exclude at the 95%
confidence level models containing the following new particles: axigluons and
flavor universal colorons with mass between 200 and 980 GeV/c, excited quarks
with mass between 80 and 570 GeV/c^2 and between 580 and 760 GeV/c^2, color
octet technirhos with mass between 260 and 480 GeV/c^2, W' bosons with mass
between 300 and 420 GeV/c^2, and E_6 diquarks with mass between 290 and 420
GeV/c^2.Comment: 18 pages, 4 figures, 1 table. Submitted to Physical Review D Rapid
Communications. Postscript file of paper is also available at
http://www-cdf.fnal.gov/physics/pub97/cdf3276_dijet_search_prd_rc.p
Relationship between the Clinical Frailty Scale and short-term mortality in patients ≥ 80 years old acutely admitted to the ICU: a prospective cohort study.
BACKGROUND: The Clinical Frailty Scale (CFS) is frequently used to measure frailty in critically ill adults. There is wide variation in the approach to analysing the relationship between the CFS score and mortality after admission to the ICU. This study aimed to evaluate the influence of modelling approach on the association between the CFS score and short-term mortality and quantify the prognostic value of frailty in this context. METHODS: We analysed data from two multicentre prospective cohort studies which enrolled intensive care unit patients ≥ 80 years old in 26 countries. The primary outcome was mortality within 30-days from admission to the ICU. Logistic regression models for both ICU and 30-day mortality included the CFS score as either a categorical, continuous or dichotomous variable and were adjusted for patient's age, sex, reason for admission to the ICU, and admission Sequential Organ Failure Assessment score. RESULTS: The median age in the sample of 7487 consecutive patients was 84 years (IQR 81-87). The highest fraction of new prognostic information from frailty in the context of 30-day mortality was observed when the CFS score was treated as either a categorical variable using all original levels of frailty or a nonlinear continuous variable and was equal to 9% using these modelling approaches (p < 0.001). The relationship between the CFS score and mortality was nonlinear (p < 0.01). CONCLUSION: Knowledge about a patient's frailty status adds a substantial amount of new prognostic information at the moment of admission to the ICU. Arbitrary simplification of the CFS score into fewer groups than originally intended leads to a loss of information and should be avoided. Trial registration NCT03134807 (VIP1), NCT03370692 (VIP2)
Further Properties of High-Mass Multijet Events at the Fermilab Proton-Antiproton Collider
The properties of high-mass multijet events produced at the Fermilab
proton-antiproton collider are compared with leading order QCD matrix element
predictions, QCD parton shower Monte Carlo predictions, and the predictions
from a model in which events are distributed uniformly over the available
multibody phase-space. Multijet distributions corresponding to (4N-4) variables
that span the N-body parameter space are found to be well described by the QCD
calculations for inclusive three-jet, four-jet, and five-jet events. The
agreement between data, QCD Matrix Element calculations, and QCD parton shower
Monte Carlo predictions suggests that 2 -> 2 scattering plus gluon radiation
provides a good first approximation to the full LO QCD matrix element for
events with three, four, or even five jets in the final state.Comment: 49 pages with 19 figures. Submitted to Phys. Rev. D. PostScript with
full resolution figures also available at
http://www-cdf.fnal.gov/physics/pub96/cdf3480_multijet_prd_draft3.p
Measurement of correlated jet cross sections in collisions at TeV
We report on measurements of differential cross sections,
where the muon is from a semi-leptonic decay and the is
identified using precision track reconstruction in jets. The semi-differential
correlated cross sections, d/d\Et^{{\bar b}}, d/d\pt^{{\bar
b}}, and d/d for \pt^{\mu}>~9 GeV/c,
~10 GeV, ~1.5, are
presented and compared to next-to-leading order QCD calculations.Comment: Uses Latex, Article 12 point, figures appended as uuencoded file The
full PostScript available via WWW at
http://www-cdf.fnal.gov/physics/pub95/cdf3164_mu_bbar_prd_final.p
Measurement of the Meson Differential Cross Section, , in Collisions at TeV
This paper presents the first direct measurement of the meson
differential cross section, , in collisions at
TeV using a sample of pb accumulated by
the Collider Detector at Fermilab (CDF). The cross section is measured in the
central rapidity region GeV/ by fully
reconstructing the meson decays and , where and .
A comparison is made to the theoretical QCD prediction calculated at
next-to-leading order.Comment: 14 pages. Submitted to Phys. Rev. Lett. The postscript file is at
http://www-cdf.fnal.gov/physics/pub95/cdf2893_bexcl_xsection.p
The Charge Asymmetry in W-Boson Decays Produced in p-pbar Collisions at sqrt(s) = 1.8 TeV
The charge asymmetry has been measured using decays recorded by
the CDF detector during the 1992-93 run of the Tevatron Collider. The asymmetry
is sensitive to the ratio of and quark distributions to at
, where nonperturbative effects are minimal. It is found
that of the two current sets of parton distributions, those of Martin, Roberts
and Stirling (MRS) are favored over the sets most recently produced by the CTEQ
collaboration. The asymmetry data provide a stronger constraints on
ratio than the recent measurements of which are
limited by uncertainties originating from deutron corrections.Comment: to be published in PR
Limits on and couplings from and production in collisions at TeV
Direct limits are set on and three-boson couplings in a
search for and production with high transverse momentum in
collisions at TeV, using the Collider Detector
at Fermilab. The results are in agreement with the SU(2) U(1) model of
electroweak interactions. Assuming Standard Model coupling, the the
limits are interpreted as direct evidence for a non-zero coupling at
subprocess energies near 500 GeV. Alternatively, assumiong identical and
couplings, bounds and are obtained at CL for a form factor scale 1000 GeV.Comment: 16 pages, submitted to PRL, URL:
http://www-cdf.fnal.gov/physics/pub95/cdf2951_vvprl.p
Study of ttbar Production in ppbar Collisions Using Total Transverse Energy
We analyze a sample of W + jet events collected with the Collider Detector at
Fermilab (CDF) in ppbar collisions at sqrt(s) = 1.8 TeV to study ttbar
production. We employ a simple kinematical variable "H", defined as the scalar
sum of the transverse energies of the lepton, neutrino and jets. For events
with a W boson and four or more jets, the shape of the "H" distribution
deviates by 3.8 standard deviations from that expected from known backgrounds
to ttbar production. However this distribution agrees well with a linear
combination of background and ttbar events, the agreement being best for a top
mass of 180 GeV/c^2.Comment: Postscript file (gzip+uuencode). 5-page, two-column PRL format
(RevTex). Submitted to Phys. Rev. Lett. 09 June 199
Search For Charged Higgs Decays of the Top Quark Using Hadronic Decays of the Tau Lepton
This Letter describes a direct search for charged Higgs boson production in
proton-antiproton collisions at sqrt(s)=1.8 TeV recorded by the Collider
Detector at Fermilab. Two-Higgs-doublet extensions to the standard model
predict the existence of charged Higgs bosons. In such models, the branching
fraction for top quarks B(t --> H b --> tau nu b) can be large. This search
uses the hadronic decays of the tau lepton in this channel to significantly
extend previous limits on charged Higgs production.Comment: 6pages, 4 figures, 1 table; LaTeX; submitted to PR
- …